Zebra Medical Vision names new CEO

Zebra Medical Vision has appointed Ohad Arazi as the company’s new CEO, a move that will be effective beginning March 1. Arazi has previously worked for McKesson Technology Solutions, Change Healthcare and TELUS Health.

“Every CEO dreams of being able to drive the evolution of a company from such a position of material strength,” Arazi said in a prepared statement. “As we expand our footprint in North America, the breadth of Zebra-Med’s products and compelling regulatory advantage will allow us to scale extraordinarily fast. I am thankful for the opportunity to lead one of the most exciting teams in healthcare today, and to leverage artificial intelligence to affect change for the medical imaging industry worldwide.”

Arazi is succeeding Eyal Gura, the company’s co-founder, in this position. Gura will remain in place as Zebra-Med’s chairman of the board.

 “Ohad Arazi's appointment is a clear reflection of the strong vector the Zebra Medical Vision team has created, as we’re ready to take on the future after another strong year of product innovation, unique regulatory progress, and customer successes,” Gura said in the same statement. “Zebra-Med is poised for major expansion in the medical imaging domain, and we're confident that Ohad's unique experience in turning innovative technologies into scalable and impactful products will drive significant growth for us.”

Other recent AI in Healthcare coverage of Zebra-Med can be read here and here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.